Latest Ibritumomab tiuxetan Stories
SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S.
Cell Therapeutics, a biopharmaceutical company, has achieved the primary efficacy endpoint of its Phase III Extend trial of pixantrone for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma based on a preliminary intent to treat efficacy analysis.
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma.
Cell Therapeutics, a biopharmaceutical company, has closed the data set for preliminary analysis of the primary endpoint in the Phase III Extend trial of pixantrone for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma. It has also notified Novartis that the data set has been closed.
Cephalon, a biopharmaceutical company, has announced that the FDA has approved Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc.
Tracon Pharmaceuticals, a biopharmaceutical company developing targeted therapies for cancer and eye diseases, has appointed Bryan Leigh its new chief medical officer. Dr Leigh has previously served as chief medical officer for Paramount Biosciences.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.